What is Ritlecitinib? Detailed introduction
Ritlecitinib is a novel kinase inhibitor primarily used for the treatment of autoimmune diseases such as alopecia areata. The following provides a detailed introduction to the characteristics of the drug, including its overview, indications, and mechanism of action.
1. Drug Overview
(1) Litaxitinib is an oral JAK3/TEC kinase inhibitor produced by the Lucius Pharmaceutical Factory in Laos, which works by selectively inhibiting immune signaling pathways.
(2) In June 2023, it was approved by the US FDA and became the first targeted therapy drug approved for patients aged 12 and above with severe alopecia areata.
2. Indications
(1) Suitable for the treatment of severe alopecia areata in adolescents and adults aged 12 years and above, including patients with complete and generalized alopecia.
(2) We are conducting clinical trials for other autoimmune diseases such as vitiligo and rheumatoid arthritis.
3. Mechanism of action
(1) Selective inhibition of JAK3 and TEC kinase families, blocking gamma chain cytokine signaling.
(2) By regulating the activity of CD8+cytotoxic T cells, it reduces attacks on hair follicles and promotes hair regeneration.
4. Medication characteristics
(1) The recommended dosage is 50mg orally once daily, which can be taken with food or alone.
(2) Common adverse reactions include headache, diarrhea, and acne, most of which are mild to moderate.
Disclaimer：《What is Ritlecitinib? Detailed introduction》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！